NCT02939872View on ClinicalTrials.gov

Optimal Duration of Antiplatelet Therapy After Bioresorbable Vascular Scaffold Implantation to Reduce Late Coronary Arterial Thrombotic Events

PHASE4CompletedINTERVENTIONAL

Enrollment

238

Participants

Timeline

Start Date

March 9, 2017

Primary Completion Date

May 9, 2021

Study Completion Date

June 3, 2024

Conditions

Percutaneous Transluminal Coronary AngioplastyCoronary Disease

Interventions

DRUG

aspirin and clopidogrel

at the discretion of investigator

DRUG

Clopidogrel only

at the discretion of investigator

Trial Locations (2)

138-736

Asan Medical Center, Seoul

Unknown

Chonnam National University Hospital, Gwangju

All Listed Sponsors

collaborator

CardioVascular Research Foundation, Korea

OTHER

lead

Seung-Jung Park

OTHER

NCT02939872 - Optimal Duration of Antiplatelet Therapy After Bioresorbable Vascular Scaffold Implantation to Reduce Late Coronary Arterial Thrombotic Events | Biotech Hunter | Biotech Hunter